Evox Therapeutics Ltd.

Brings foundational experience in mRNA and LNP therapeutics given prior executive leadership roles at Moderna & Alnylam Will take an active role in expanding partnerships with biopharma Integrated partnership offering to customers remains etherna’s key differentiator – Proprietary customized mRNA chemistry and lipid nanoparticles (customized LNPs) expertise combined with GMP process knowhow Niel, Belgium, July 09, 2024 – etherna (“the Company”), a leading mRNA technologies company, today announced the appointment of Antonin (Tony) de Fougerolles as Chair. Tony has served as an Independent Board Member since January 2023. Outgoing Chair, Marijn Dekkers will remain on the Board. In addition to his role as Chair, Tony will also take an active consultancy role for the Company. Bernard Sagaert, etherna CEO said: “I am absolutely thrilled to be able to work more closely with Tony. His vast experience, connections and strategic vision in the field will further accelerate the development and success of the Company. I also want to thank Marijn for the close collaboration over the last 8 months, which has been inspirational.” Tony de Fougerolles, etherna Chair added: “Over the last 18 months I have seen first-hand how the cLNPs and mRNA manufacturing expertise that etherna has developed is world leading and impressive in its quality, breadth, and novelty. The recently announced partnership with Almirall is clear recognition of this. I am excited to accept the role of Chair and look forward to actively helping Bernard and his talented team take full advantage of the exciting opportunities to help our partners bring novel mRNA-based therapeutics to patients. Marijn Dekkers, etherna Independent Board Member noted: “Tony has already proven to be an extremely valued addition to the Board and therefore I am delighted to welcome him as my successor. His combination of scientific and entrepreneurial excellence as well as clear strategic vision will enable him, I believe, to steer etherna successfully through the next stage of its development.” Tony de Fougerolles has foundational experience in both mRNA therapeutics and LNPs specifically through his roles at Moderna and Alnylam. He has nearly 25 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities to the market (mRNA, RNAi, single domain antibodies) and in helping build several multi-billion-dollar companies from start-up stage. As founding Chief Scientific Officer (CSO) at Moderna Therapeutics, he pioneered modified mRNA as a new therapeutic and vaccine drug modality and the mRNA chemistry and delivery systems that form the basis of the approved COVID-19 mRNA vaccines. Prior to that, as VP of Research at Alnylam, he helped develop RNA interference (RNAi) as a new drug modality, including overseeing development of the 1st approved LNP-based RNAi delivery system and the development of several approved RNAi drugs including inclisiran. Author of over 60 scientific publications and an inventor on over 110 issued US patents, Tony has also a ‘Belgian’ connection, from his time as CSO at Ablynx (now Sanofi) where he played a key role in the approval of the 1st single domain antibody drug, caplacizumab. Most recently, Tony was CEO of Evox Therapeutics where he built out an exosome-focused biotech, raised over $140m in equity financing, and entered into pharma partnerships with combined upfronts > $60m and total deal value >$2 billion. Tony obtained his PhD in Immunology from Harvard University. -ends- For further information, please contact: etherna Bernard Sagaert media@etherna.be RHA Communications Richard@rhacomms.eu Notes to Editors About etherna etherna is an mRNA technology platform company with fully integrated capabilities including mRNA construct design and optimization, coupled with specialized expertise in designing and manufacturing customized lipid nanoparticles (cLNP) formulations tailored for the prevention and treatment of various pathological states, providing end-to-end solutions for next generation mRNA therapeutics. The company offers this knowledge and know-how in a partnership model to drive discovery and solve challenges for partners across LNP formulation and RNA chemistry to enable delivery of cost-effective, differentiated and efficacious RNA therapeutics.

Researchers have succeeded in delivering targeted cancer treatment via small membrane bubbles that our cells use to communicate. A new study shows that the treatment reduces tumor growth and improves survival in mice. Researchers at Karolinska Institutet in Sweden have succeeded in delivering targeted cancer treatment via small membrane bubbles that our cells use to communicate. A new study published in Nature Biomedical Engineering shows that the treatment reduces tumour growth and improves survival in mice. When our cells communicate, they send out small membrane bubbles known as extracellular vesicles which contain various signalling molecules. Interest in these tiny bubbles, sometimes referred to as the body's 'message in a bottle', has increased in recent years as they could be used to deliver medicines. Antibodies seek out tumours Researchers at Karolinska Institutet have now created a targeted cancer treatment by loading these bubbles with a chemotherapeutic drug and attaching antibodies against tumours to their surface. In addition to targeting tumour cells, the antibodies act as a form of immunotherapy, resulting in an enhanced therapeutic effect. The treatment reduced tumour growth and improved survival when given as an injection to mice with breast cancer or melanoma. "By attaching different antibodies to extracellular vesicles, we can target them to virtually any tissue and we can load them with other types of drugs as well," says Oscar Wiklander, physician and researcher at the Department of Laboratory Medicine, Karolinska Institutet, and joint first author with Doste Mamand, researcher at the same department. "Therefore, the treatment has the potential to be used against other diseases and cancer types." More effective and fewer side effects The hope is that the new treatment will be more specific and effective in eliminating tumour cells without affecting healthy tissue, compared to current treatment strategies. The researchers plan to investigate whether different combinations of antibodies and drugs can further improve treatment. "Among other things, we want to investigate the possibility of delivering mRNA as an anticancer drug," says the study's last author Samir EL Andaloussi, Professor at the Department of Laboratory Medicine, Karolinska Institutet. "Ultimately, we hope this can lead to a new treatment platform that can improve treatment efficacy and reduce side effects in difficult-to-treat diseases, especially cancer." The research was mainly funded by the Swedish Cancer Society, the Swedish Research Council, the European Research Council (ERC) and CIMED. Several of the authors have a financial interest in Evox Therapeutics.

OXFORD, United Kingdom, April 29, 2024 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces that Dr. Per Lundin, Co-Founder and Chief Business Officer, has been appointed as Chief Executive Officer (CEO) of the Company and will be appointed to its Board of Directors. Following more than six years with the Company, Dr. Antonin “Tony” de Fougerolles has decided to step down as CEO and Director of Evox. Tony will continue to support the Company as a strategic adviser. Per has more than 15 years’ experience founding, leading, and advising biotech companies developing advanced therapies, including co-founding Evox in 2016. Prior to Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, and prior to that worked in business development and as an IP attorney in a leading European law firm. Per serves as non-executive director of publicly listed gene therapy company Combigene and research committee member and board director of JDRF International and JDRF UK, respectively. He is a qualified European Patent Attorney with extensive leadership, business development and operational experience; he earned his PhD from the Karolinska Institute, his Master of Science in Biotechnology Engineering from the Royal Institute of Technology, and his Master of Business Administration from Stockholm University School of Business. Per takes on the role of CEO having founded the Company in 2016 and worked closely with Tony over the last six and a half years to significantly progress the business. Evox is backed by leading venture capital investors and has since inception developed a proprietary exosome therapeutics platform technology, entered into a number of collaborations with renowned institutions and pharma companies, developed a dominant IP estate and advanced the Company’s proprietary pipeline towards the clinic. “On behalf of the Board and the whole Evox team, I would like to thank Tony for his leadership and commitment to driving the Company and its innovative technology forward, and wish him all the best in the next phase of his career,” said Paul Carter, Non-Executive Chairman of Evox Therapeutics. “Per’s strategic insight and wide-ranging experience will be invaluable as he leads Evox through its next phase of growth. Furthermore, as Co-Founder of the business, he has a deep understanding of Evox and its exosome platform.” “Over the past six and a half years as CEO, I am extremely proud of the progress we have made to uncover the enormous potential of exosome therapeutics,” said Dr. Antonin de Fougerolles, outgoing CEO. “The Company has a very promising future ahead and I look forward to continuing to support Evox’s journey in an advisory role.” Per Lundin, PhD, Chief Executive Officer and Co-Founder of Evox Therapeutics, added: “I have enjoyed working closely with Tony over the years and I look forward to leading the Company as we advance our cutting-edge technology, DeliverEX®, to accelerate the development of exosome-enabled genetic medicines.” About Evox Therapeutics Evox Therapeutics is a privately held, Oxford-based biotechnology company that is a leader in harnessing and engineering the natural delivery capabilities of exosomes to create and enable the next generation of genetic medicines. Evox uses its DeliverEX® platform to engineer exosomes to facilitate safe and precise drug delivery to hard-to-reach organs and tissues. The Company holds an unrivalled intellectual property estate across non-viral genetic medicines and is backed by leading life sciences venture capital groups, including Oxford Science Enterprises, Redmile, OrbiMed and GV. For media enquiries, please contact: Media:Simon Conway / Natalie Garland-CollinsEvoxTherapeutics@fticonsulting.com +44 (0) 203 727 1000 For further information visit: www.evoxtherapeutics.com